Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum

British Journal of Pharmacology

Volumn 146, Issue 2, 2005, Pages 259-267

  Matsumoto, Kenshi ^a,b   Yoshida, Masaki ^b   Andersson, Karl Erik ^a   Hedlund, Petter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

adrenoceptors; Apomorphine; Corpus cavernosum; Dopamine receptors; Rat; Relaxation

Indexed keywords

APOMORPHINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ENDOTHELIN 1; KETAMINE; PENTOBARBITAL; PHENYLEPHRINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE RESPONSE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NONHUMAN; PENIS ERECTION; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT; WAKEFULNESS;

ANIMALS; APOMORPHINE; CYCLIC AMP; CYCLIC GMP; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENDOTHELIN-1; GUANOSINE; INJECTIONS; ISOMETRIC CONTRACTION; MALE; MUSCLE CONTRACTION; MYOGRAPHY; PENILE ERECTION; PENIS; RATS; RATS, SPRAGUE-DAWLEY; WAKEFULNESS;

EID: 30544445518     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706317     Document Type: Article

References (43)

1. ABARCA, B., BALLESTEROS, R., BIELSA, P., MORAGUES, J., D'OCON, P., GARCIA-ZARAGOZÀ, E. & NOGUERA, M.A. (2003). Opposite vascular activity of (R)-apomorphine and its oxidised derivatives. Endothelium-dependent vasoconstriction induced by the auto-oxidation metabolite. Eur. J. Med. Chem., 38, 501-511.
2. AMENTA, F., BARILI, P., BRONZETTI, E., FELICI, L., MIGNINI, F. & RICCI, A. (2000). Localization of dopamine receptor subtypes in systemic arteries. Clin. Exp. Hypertens., 22, 277-288.
3. ANDERSSON, K.-E. (2001). Pharmacology of penile erection. Pharmacol. Rev., 53, 417-450.
4. ANWAR, N. & MASON, D.F. (1981). Actions of dopamine and apomorphine on the vasoconstrictor responses of perfused mesenteric arteries of mouse, rat and rabbit. J. Pharm. Pharmacol., 33, 150-154.
5. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
6. DAVENPORT, A.P. (2002). International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev., 54, 219-226.
7. D'EMMANUELE DI VILLA BIANCA, R., SORRENTINO, R., ROVIEZZO, F., IMBIMBO, C., PALMIERI, A., DE DOMINICIS, G., MONTORSI, F., CIRINO, G. & MIRONE, V. (2004). Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips. Int. J. Impot. Res., 17, 127-133.
8. GIULIANO, F., ALLARD, J., RAMPIN, O., DROUPY, S., BENOIT, G., ALEXANDRE, L. & BERNABE, J. (2001). Spinal proerectile effect of apomorphine in the anesthetized rat. Int. J. Impot. Res., 13, 110-115.
9. GIULIANO, F. & RAMPIN, O. (2000). Central neural regulation of penile erection. Neurosci. Biobehav. Rev., 24, 517-533.
10. GUIMARAES, S. & MOURA, D. (2001). Vascular adrenoceptors: an update. Pharmacol. Rev., 53, 319-356.
11. GYORGY, L. & DODA, M. (1985). The effect of dopamine, apomorphine and pirebedil on the mesenterial blood flow of the cat. Arch. Int. Pharmacodyn. Ther., 275, 22-32.
12. HAN, G., KRYMAN, J.P., MCMILLIN, P.J., WHITE, R.E. & CARRIER, G.O. (1999). A novel transduction mechanism mediating dopamine-induced vascular relaxation: opening of BKCa channels by cyclic AMP-induced stimulation of the cyclic GMP-dependent protein kinase. J. Cardiovasc. Pharmacol., 34, 619-627.
13. HEDLUND, H., ANDERSSON, K.-E. & MATTIASSON, A. (1984). Pre- and postjunctional adreno- and muscarinic receptor functions in the isolated human corpus spongiosum urethrae. J. Auton. Pharmacol., 4, 241-249.
14. HEDLUND, P., ALM, P. & ANDERSSON, K.-E. (1999). NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br. J. Pharmacol., 127, 349-360.
15. HIETALA, J. (1988). Effects of DA-1- and DA-2-dopamine antagonists on apomorphine-induced inhibition of peripheral sympathetic neurotransmission. J. Auton. Pharmacol., 8, 297-302.
16. HSIEH, G.C., HOLLINGSWORTH, P.R., MARTINO, B., CHANG, R., TERRANOVA, M.A., O'NEILL, A.B., LYNCH, J.J., MORELAND, R.B., DONELLY-ROBERTS, D.L., KOLASA, T., MIKUSA, J.P., MCVEY, J.M., MARSH, K.C., SULLIVAN, J.P. & BRIONI, J.D. (2004). Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J. Pharmacol. Exp. Ther., 308, 330-338.
17. HUGHES, A.D., THOM, S.A., WOODALL, N.M., REDMAN, D. & SEVER, P.S. (1987). Dopamine produces forearm vasodilation following alpha-adrenoreceptor blockade by an action on vascular dopamine (DA-1) receptors in man. J. Hypertens., 5, 337-340.
18. HUGHES, A., THOM, S., MARTIN, G., REDMAN, D., HASAN, S. & SEVER, P. (1986). The action of dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br. J. Clin. Pharmacol., 22, 535-540.
19. HULL, E.M., LORRAIN, D.S., DU, J., MATUSZEWICH, L., LUMNLEY, L.A., PUTNAM, S.K. & MOSES, J. (1999). Hormone-neurotransmitter interactions in the control of sexual behaviour. Behav. Brain Res., 105, 105-116.
20. HYUN, J.S., BIVALACQUA, T.J., BAIG, M.R., YANG, D.Y., LEUNGWATTANAKIJ, S., ABDEL-MAGEED, A., KIM, K.D. & HELLSTRÖM, W.J. (2002). Localization of peripheral dopamine D1 and D2 receptors in rat corpus cavernosum. Br. J. Pharmacol. Int., 90, 105-112.
21. KOPIA, G.A. & VALOCIK, R.E. (1989). Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog. J. Pharmacol. Exp. Ther., 248, 215-221.
22. LEVANT, B. (1997). The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev., 49, 231-252.
23. MILLAN, M.J. (2000). Improving the treatment of schizophrenia; focus on serotonin (5-HT)1A receptors. J. Pharmacol. Exp. Ther., 295, 853-861.
24. MILLAN, M.J., MAIOFISS, L., CUSSAC, D., AUDINOT, V., BOUTIN, J.A. & NEWMAN TANCREDI, A. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned receptor subtypes. J. Pharmacol. Exp. Ther., 303, 791-804.
25. 1D-adrenoceptor antagonist. Br. J. Pharmacol., 136, 701-708.
26. MOLDERINGS, G.J., GOTHERT, M., VAN AHLEN, H. & PORST, H. (1989). Noradrenaline release in human corpus cavernosum and its modulation via presynaptic alpha 2-adrenoreceptors. Fund. Clin. Pharmacol., 3, 497-504.
27. MORGADINHO, M.T., FONTES RIBEIRO, C.A. & MACEDO, T.R. (1999). Presynaptic dopamine receptors involved in the inhibition of noradrenaline and dopamine release in the human gastric and uterine arteries. Fund. Clin. Pharmacol., 13, 662-670.
28. MUHLBAUER, B., KUSTER, E. & LUIPPOLD, G. (2000). Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiol. Scand., 168, 219-223.
29. MURPHY, M.B. (2000). Dopamine: a role in the pathogenesis and treatment of hypertension. J. Hum. Hypertens, 14 (Suppl 1), S47-S50.
30. 2-adrenoceptor. J. Pharmacol. Exp. Ther., 303, 805-814.
31. +-pump activity by dopamine in rat tail arteries. Eur. J. Pharmacol., 33, 150-154.
32. SIBLEY, D.R. (1999). New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu. Rev. Pharmacol. Toxicol., 39, 313-341.
33. SIMPSON, M.M., BALLESTEROS, J.A., CHIAPPA, V., CHEN, J., SUEHIRO, M., HARTMAN, D.S., GODEL, T., SNYDER, L.A., SAKMAR, T.P. & JAVITCH, J.A. (1999). Dopamine D4/D2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol. Pharmacol., 56, 1116-1126.
34. SOARES-DA-SILVA, P. (1987). Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels. Br. J. Pharmacol., 91, 591-599.
35. STRANGE, P.O. (2001). Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev., 53, 119-133.
36. TEISMAN, A.C., BUIKEMA, H., VAN VELDHUISEN, D.J., DE ZEEUW, D. & VAN GILST, W.H. (2000). Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. J. Cardiovasc. Pharmacol., 35, 581-585.
37. VAN DER NIEPEN, P., SCHOORS, D.F. & DUPONT, A.G. (1991). Hypotensive and regional hemodynamic effects of the dopamine receptor agonist SK & F 85174 in the anesthetized rat. Arch. Int. Pharmacodyn. Ther., 313, 98-107.
38. VAN TOL, H.H., BUNZOW, J.R., GUAN, H.C., SUNAHARA, R.K., SEEMAN, P., NIZNIK, H.B. & CIVELLI, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (London), 350, 610-614.
39. VENTURA, A.L., KLEIN, W.L. & DE MELLO, F.G. (1984). Differential ontogenesis of D1 and D2 dopaminergic receptor in the chick embryo retina. Brain Res., 314, 217-223.
40. VILLALON, C.M., RAMIREZ-SAN JUAN, E., SANCHEZ-LOPEZ, A., BRAVO, G., WILLEMS, E.W., SAXENA, P.R. & CENTURION, D. (2003). Pharmacological profile of the vascular responses to dopamine in the canine external carotid circulation. Pharmacol. Toxicol., 92, 165-172.
41. 2A-adrenergic receptor. Mol. Pharmacol., 59, 532-542.
42. WINGARD, C.J., HUSAIN, S., WILLIAMS, J. & JAMES, S. (2003). RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am. J. Physiol. Regul. Integr. Comp. Physiol., 285, R1145-R1152.
43. ZENG, C., WANG, D., YANG, Z., WANG, Z., ASICO, L.D., WILCOX, C.S., EINSNER, G.M., WELCH, W.J., FELDER, R.A. & JOSE, P.A. (2004). Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension, 43, 673-679.